

Mediso opens a new frontier in preclinical tri-modality imaging by introducing its new nanoScan® SPECT/CT/PET.

Savannah, GA, USA – Sept. 18, 2013 – Mediso Medical Imaging Systems announces nanoScan® SPECT/CT/PET triple modality system as the latest member of its nanoScan® Family of integrated pre-clinical molecular imaging equipment at the World Molecular Imaging Congress (WMIC), 2013, in Savannah, USA.

The novelty of the nanoScan® SPECT/CT/PET is the unprecedented versatility in configuration that satisfies a wide range of demands from the customers: “We listened to researchers needs, when developing a triple modality imaging system, which allows core facilities with a wide application spectrum but limited budget to cover all modalities in molecular imaging. At the same time we emphasize the unique upgrade opportunity that paves the way to high performance nanoScan® features including MRI modality to allow outstanding soft tissue contrast” says **Mr Illes Muller**, managing partner of Mediso USA, the affiliate of Mediso Ltd. responsible for the North American operations.

The nanoScan® SPECT/CT/PET perfectly satisfies the need for quantified imaging in all preclinical application areas such as: tumor biology, receptor studies in neuroscience, inflammation and immunology, and development of radiotracers and contrast agents. "The nanoScan® SPECT/CT/PET integrates our proprietary and patented* M³-pinhole™ technology and Tera-Tomo™ 3D SPECT and PET reconstruction algorithm with high-performance CT system" says **Mr István Bagaméry**, founder and CEO of Mediso.

The first member of the nanoScan® Family the nanoScan® PET/MRI was introduced in 2011 to create a versatile molecular imaging platform which was awarded with the Frost and Sullivan European Preclinical Imaging New Product Innovation award. In the following years the nanoScan® PET/CT, SPECT/CT and SPECT/MRI continued the line with the fifth member the nanoScan® SPECT/CT/PET launched now. Through its shared accessories such as common software and animal handling the nanoScan® imagers will simplify and speed up daily work of researchers.

The nanoScan® Family features the same universal MultiCell™ animal handling platform and the intuitive InterView™ FUSION software package that accounts for the unparalleled user experience. All systems share a single, integrated framework for raw data acquisition, image reconstruction and archiving. Quantitative imaging is supported by the Tera-Tomo™ multi-GPU based reconstruction algorithm with all corrections including CT or MRI based attenuation and scatter correction.

The MultiCell™ imaging chambers are available for all modalities ensuring temperature control and physiological monitoring of wide range of experimental animals. The new PrepaCell™ animal preparation station is also a big step

towards efficient animal management and increased throughput.

The nanoScan® SPECT/CT/PET in-line multimodality pre-clinical imager is developed, manufactured and distributed by Mediso worldwide, further details can be gathered at the World Molecular Imaging Congress (WMIC) in Savannah, Georgia, US at Mediso's booth #313.

About Mediso Ltd.:

Mediso is one of the World's largest manufacturers and suppliers of multimodality hybrid imaging devices. Mediso was founded in 1990 by experts with experience in R&D and manufacturing of nuclear equipment. Currently Mediso offers four imaging modalities - SPECT, PET, CT, MRI - for professionals working in laboratories and nuclear medicine departments. Mediso products are sold worldwide directly and through a network of distributors. There are more than 1000 imaging systems operating in more than 85 countries around the world. For more information, please visit the Mediso web site at www.medisoinc.com